Tuesday, September 22, 2020, 8:00 AM - Tuesday, September 21, 2021, 11:59 PM


AMA PRA Category 1 Credits™ (0.50 hours), AMA PRA Category 1 Credits™ Designated (0.50 hours)

Severe asthma is linked to significant morbidity, health care resource utilization, and long-term sequelae including airway remodeling and a greater risk of developing chronic obstructive pulmonary disease. These consequences emphasize the importance of improved identification and management of patients with severe asthma. Treatment guidelines may be confusing and it may be challenging to keep abreast of new developments. Routine assessments of lung function, frequency and severity of exacerbations, symptom control, and medication adherence are pivotal to provide necessary information for identifying and determining the most appropriate management strategy. An increased understanding of asthma pathophysiology and its correlation to disease activity has identified therapeutic targets. Biologic therapies that target T2 pathways and new supportive digital health technologies mark a new era in asthma management and treatment.

1. Distinguish between asthma control and asthma severity to identify patients with severe asthma based on an understanding of epidemiologic data and ongoing evaluations of symptoms, potential disease phenotypes, and treatment history;
2. Assess the clinical data of newer and emerging cytokine-targeting biologic medications in the treatment of severe asthma;
3. Recognize the benefits of facilitating communication with patients and their caregivers and coordinating with specialists to personalize therapy for patients with severe asthma.

There are no fees for participating in and receiving CME credit for this online activity. 

To participate in this activity, register with ReachMD.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and CORE Medical Education, LLC. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

The University of Cincinnati designates this enduring material activity for a maximum of .50 AMA PRA Category 1 Credit™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

CME FRONT MATTER

Faculty & Disclosure / Conflict of Interest Policy
According to the disclosure policy of the University of Cincinnati College of Medicine, all faculty, planning committee members, and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interest related to this activity. All educational materials are reviewed for fair balance, scientific objectivity and levels of evidence. Disclosure will be made at the time of activity.

Medical Director & Program Planners

CORE Medical Education, LLC
Otto Ratz, MD
Christina Culbert, MSc

University of Cincinnati Continuing Medical Education Office
Bruce Gebhardt, MD, Professor, Physician Reviewer
Susan P. Tyler, PhD, MEd, CMP, CHCP, Director
Heather Muskopf, Program Manager

CORE Medical Education and the University of Cincinnati  have no relevant conflict of interest to report.

Disclaimer Statement
The opinions expressed during the endured activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati. The information is presented for the purpose of advancing the attendees’ professional development.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Neither the University of Cincinnati College of Medicine nor CORE Medical Education, LLC, recommends the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati College of Medicine or CORE Medical Education, LLC. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Learner Assurance Statement
The University of Cincinnati is committed to resolving all conflicts of interest issues that could arise as a result of prospective faculty members’ relationships with drug or device manufacturer(s). The University of Cincinnati is committed to retaining only those speakers with financial interests that can be reconciled with the goals and educational integrity of the CME activity.

Off-Label Disclosure Statement
Faculty members are required to inform the audience when they are discussing off-label, unapproved uses of devices and drugs. Physicians should consult full prescribing information before using any product mentioned during this educational activity.

The registration form for this activity is currently unavailable.

This program is supported by an educational grant from Genentech, Inc. and AstraZeneca.